Xenetic Biosciences, Inc. Announces Positive Data from Partner's Pivotal Phase 3 Clinical Trial Utilizing PolyXen(R) Platform Technology

Stock Information for Xenetic Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Xenetic Biosciences Inc.

Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results
Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
Xenetic Biosciences, Inc. Reports Third Quarter 2023 Financial Results
Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Xenetic Biosciences, Inc. Reports Second Quarter 2023 Financial Results
Xenetic Biosciences, Inc. to Participate in the Virtual Investor Summer Spotlight Series
Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.